TY - JOUR
T1 - Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer
AU - Nakamori, Shoji
AU - Endo, Wakio
AU - Ozato, Hiroki
AU - Shibata, Takashi
AU - Takeda, Yutaka
AU - Tohno, Ken
AU - Hasuike, Yasunori
AU - Masutani, Seizo
AU - Morimoto, Takashi
AU - Doki, Yuichirou
AU - Mori, Masaki
AU - Monden, Morito
PY - 2011/5/15
Y1 - 2011/5/15
N2 - Our objective was to evaluate the efficacy and toxicity of the pre-administration of UFT (uracil/tegafur: prodrug of 5-FU) and GEM combination therapy for unresectable/recurrent pancreatic cancer in the outpatient setting. UFT (250 mg/m2/day) was orally administered from day 1 through day 6 and from day 8 through 13, and GEM (800 mg/m2, div/30min) was administered on day 7 and 14, with a one-week rest every 3 weeks based on results of the previous phase I study. Thirty-six pts (24 male, 12 female) were enrolled (median age, 63.8 yrs). There were 8 partial responses (25%). Eighteen pts (56%) had stable disease, and 6 pts (19%) had a progression. The median survival time was 7.0 months (range 1.5-66). Grade 3 toxicities were leucopenia (17%), thrombocytopenia (3%), nausea (3%), and liver dysfunctions (3%). There were no Grade 4 toxicities. Pre-administered UFT plus GM is a promising treatment for unresectable/recurrent pancreatic cancer in the outpatient setting.
AB - Our objective was to evaluate the efficacy and toxicity of the pre-administration of UFT (uracil/tegafur: prodrug of 5-FU) and GEM combination therapy for unresectable/recurrent pancreatic cancer in the outpatient setting. UFT (250 mg/m2/day) was orally administered from day 1 through day 6 and from day 8 through 13, and GEM (800 mg/m2, div/30min) was administered on day 7 and 14, with a one-week rest every 3 weeks based on results of the previous phase I study. Thirty-six pts (24 male, 12 female) were enrolled (median age, 63.8 yrs). There were 8 partial responses (25%). Eighteen pts (56%) had stable disease, and 6 pts (19%) had a progression. The median survival time was 7.0 months (range 1.5-66). Grade 3 toxicities were leucopenia (17%), thrombocytopenia (3%), nausea (3%), and liver dysfunctions (3%). There were no Grade 4 toxicities. Pre-administered UFT plus GM is a promising treatment for unresectable/recurrent pancreatic cancer in the outpatient setting.
UR - http://www.scopus.com/inward/record.url?scp=79960987093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960987093&partnerID=8YFLogxK
M3 - Article
C2 - 21566438
AN - SCOPUS:79960987093
SN - 0385-0684
VL - 38
SP - 789
EP - 792
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 5
ER -
